Shepherd Financial Partners LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,952 shares of the company’s stock after selling 80 shares during the quarter. Shepherd Financial Partners LLC’s holdings in Johnson & Johnson were worth $1,108,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Evolution Wealth Advisors LLC acquired a new position in Johnson & Johnson during the 4th quarter valued at about $40,000. Thor Advisors LLC acquired a new position in shares of Johnson & Johnson in the first quarter valued at about $69,000. Personal Wealth Partners acquired a new position in shares of Johnson & Johnson in the second quarter valued at about $73,000. Quattro Financial Advisors LLC acquired a new position in shares of Johnson & Johnson in the second quarter valued at about $92,000. Finally, Financial Gravity Wealth Inc. grew its holdings in Johnson & Johnson by 36.9% during the second quarter. Financial Gravity Wealth Inc. now owns 809 shares of the company’s stock worth $113,000 after acquiring an additional 218 shares during the period. Hedge funds and other institutional investors own 67.23% of the company’s stock.
In other Johnson & Johnson news, Director Marillyn A. Hewson purchased 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 11th. The stock was acquired at an average cost of $139.68 per share, with a total value of $419,040.00. Following the completion of the purchase, the director now directly owns 3,000 shares in the company, valued at approximately $419,040. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.23% of the stock is currently owned by corporate insiders.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.16. The firm had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The firm’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.10 earnings per share. As a group, equities analysts predict that Johnson & Johnson will post 8.6 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be given a $0.95 dividend. The ex-dividend date is Monday, August 26th. This represents a $3.80 dividend on an annualized basis and a yield of 2.95%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.
A number of brokerages have issued reports on JNJ. Credit Suisse Group set a $156.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday. Wells Fargo & Co reissued an “outperform” rating and set a $157.00 target price (up previously from $152.00) on shares of Johnson & Johnson in a research note on Monday, May 6th. Barclays initiated coverage on Johnson & Johnson in a report on Friday, June 21st. They issued a “hold” rating and a $140.00 target price for the company. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price target for the company. in a report on Thursday, July 18th. Finally, Goldman Sachs Group set a $169.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $150.60.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.